Nitrosamine Impurities Deadline: Are Your Products Compliant? Get more Life Science Leader insight with our FREE newsletter. sign

Ensuring Your Products Are Compliant Before The Nitrosamine Impurities Deadline Get more Life Science Leader insight with our FREE

Spectrometry For Characterization And Quantitation Of APIs And Impurities In Complex

and capabilities to meet any customer’s oral solid dose needs. ARTICLES Nitrosamine Impurities Deadline: Are Your Products

mispairing of heavy and light chains can lead to unwanted impurities that are difficult to

correct pairing of antibody chains, resulting in low yields and impurities. This not only hinders

A Mass Spec Team Using Advanced Mass Spectrometry To Analyze APIs And Impurities Navigating A New

complex products. For example, manufacturing changes may unexpectedly alter product purity (increase process-related impurities, cellular impurities, aggregates, or

exchange chromatography, both of which concentrate the product and remove impurities. Following the capture

and manufacturing. Characterizing APIs and managing a diverse population of impurities mitigates safety risks and

is on the analysis of host cell proteins and other impurities. Before joining the

a high proportion of full capsids and low levels of impurities in the

of heavy–heavy and heavy–light chains can lead to unwanted impurities that are difficult to

A may improve purity and increase the removal of impurities. This guide helps you

antibody variants. MabSelect™ VL resin allows for good resolution of product-related impurities in the

and manufacturability. The platform has demonstrated high purity and lower residual impurities, with in vitro

a Q-functional hydrogel and 0.2 μm membrane to reduce impurities in a

wash step before the elution step reduced the amount of impurities. We also performed a

about the active ingredient. While good methods can provide data on the impurities and potential

is a capsule filled with mini tablets. Two major issues related to impurities were encountered during the

to their varying binding affinities and the need to separate impurities. To address

sometimes leading to a financially unfeasible program. Product and process-related impurities increase the burden

and lower yields. More complex biologics tend to possess certain process- or product-related impurities after affinity steps that